SEATTLE, Wash., October 30, 2014 – Impel NeuroPharma is pleased toannounce that H. Stewart Parker, a prominent leader in Seattle’s Biotechnology community, has joined Impel’s Board of Directors. Most recently, Parker was the CEO of the Seattle-based Infectious Disease Research Institute (IDRI), a nonprofit global health research institute developing diagnostics, vaccines,...

March 24, 2014 – A nasal spray that delivers a new type of depression treatment holds promise as a potential alternative therapeutic approach, research from the Centre for Addiction and Mental Health (CAMH) shows. The study, led by CAMH’s Dr. Fang Liu, is published online in Neuropsychopharmacology. In a previous study published in...